Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 11/13/25
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial ResultsAccesswire • 11/13/25
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025Accesswire • 11/05/25
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)Accesswire • 09/23/25
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025Accesswire • 09/16/25
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)Accesswire • 06/25/25
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)Accesswire • 06/23/25
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization PlanAccesswire • 06/09/25
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common StockAccesswire • 06/06/25
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United StatesAccesswire • 06/06/25
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial ResultsAccesswire • 05/14/25
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025Accesswire • 05/07/25
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025Accesswire • 04/21/25
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial ResultsAccesswire • 02/12/25
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025Accesswire • 02/05/25
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025Accesswire • 01/06/25